An ephrin-A-dependent Signaling Pathway Controls Integrin Function and Is Linked to the Tyrosine Phosphorylation of a 120-kDa Protein*

Jisen Huai and Uwe DrescherDagger

From the Department of Physical Biology, Max Planck Institute for Developmental Biology, Spemannstrasse 35, 72076 Tübingen, Germany

Received for publication, September 6, 2000, and in revised form, October 16, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Eph family of receptor tyrosine kinases and their ligands, the ephrins, have been implicated in the development of the retinotectal projection. Here, glycosylphosphatidylinositol-anchored A-ephrins are not only expressed in the tectum but also on retinal axons, raising the possibility that they function in this context as receptors. We now show that activation of ephrin-A2 or ephrin-A5 by one of their receptors, ephA3, results in a beta 1-integrin-dependent increased adhesion of ephrin-A-expressing cells to laminin. In the search for an ephrin-A-dependent signaling pathway controlling integrin activation, we identified a 120-kDa raft membrane protein that is tyrosine-phosphorylated specifically after ephrin-A activation. Tyrosine phosphorylation of this protein is not seen after stimulating ephrin-A2-expressing cells with basic fibroblast growth factor, epidermal growth factor, insulin growth factor, or fetal calf serum containing a large set of different growth factors. The role of p120 as a mediator of an ephrin-A-integrin coupling is supported by the finding that inhibiting tyrosine phosphorylation of p120 correlates with an abolishment of the beta 1-dependent cell adhesion.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

During development of the retinotectal projection, members of the Eph family of receptor tyrosine kinases and their "ligands", the ephrins, are strongly involved in guiding retinal axons to, and in, the tectum (for review see Refs. 1-3). Besides the graded expression of Eph receptors on retinal axons and of ephrins in the tectum, the ephrin-As are also differentially expressed on retinal axons themselves (4, 5). Gain of function and loss of function analyses suggest that here the ephrin-As modulate the function of the coexpressed receptors in that coexpression of ligands and receptors runs in parallel to a decrease in sensitivity for the repellent activity of the tectally expressed ephrins (4, 5). These findings fit to subsequent results of in vivo analyses of ephrin-A5 single and ephrin-A5;ephrin-A2 double knockout mice (6).

A hint of how ephrin-A functions on retinal axons may be provided by the concept that these ligands are localized, because of their membrane attachment by a glycosylphosphatidylinositol (GPI)1 anchor, to so-called rafts (7-12). rafts are small dynamic microdomains in the membrane with a special glycosphingolipid and cholesterol composition, which have been proposed, besides having other functions, to serve as localized platforms for signal transduction (13).

GPI-anchored proteins are bound to the outer leaflet of the raft membranes (with no direct contact to the cytosol), whereas signaling molecules such as members of the src family are localized to the inner leaflet of rafts. In fact, "activated" GPI-anchored proteins can transduce signals to the cytosol, leading, for example, to changes in intracellular Ca2+ concentrations and activation of specific signaling pathways. This signaling might occur through formation of larger raft domains triggered by clustering of GPI-anchored proteins, which allows an interaction of signaling molecules normally separated through direct interactions between raft lipids or through (regulated) association of GPI-anchored molecules with appropriate transmembrane (co) receptors (9, 14). For example, the GPI-anchored cell adhesion molecule contactin/F11 associates with the transmembrane protein CASPR (15), representing a coreceptor involved in signal transduction after contactin/F11 stimulation. Other examples of GPI-anchored proteins capable of mediating signals include Thy-1 (16), CNTF (17), GDNF (18), and neurturin (19).

Simons and coworkers (7) have put forward the idea that a fundamental principle guiding the way raft microdomains exert their function in signal transduction is the (regulated) separation of different membrane proteins (7, 20). According to this concept, GPI-anchored molecules and other specific sets of membrane proteins have a strong tendency to associate with these domains, whereas others, such as molecules with a transmembrane domain, rarely appear in these areas.

Recently, it was shown that activation of ephrin-A5 results in an increase in adhesion of the ligand-expressing cells and in the level of tyrosine phosphorylation of molecules with molecular masses of 75-80 and 60 kDa (21). These changes, however, were not specific for an ephrin-A activation and were also seen after incubation of these cells with, for example, basic fibroblast growth factor (bFGF) (22).

Here we show that binding of the ephA3 receptor to ephrin-A2 and ephrin-A5 leads to an activation of the integrin system, as seen in a beta 1-integrin-dependent increase in adhesion of the ephrin-A-expressing cells. Activation of ephrin-As and changes in adhesion correlate well with the tyrosine phosphorylation of a protein with a molecular mass of 120 kDa, which is observed only after ephrin-A activation. p120 thus might represent a component of a new ephrin-A-dependent signaling pathway functionally linking ephrin-As to integrins.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Establishment of ephrin-A-expressing Cell Lines-- HEK293 cell clones stably expressing chick ephrin-A2 or the long or the short form of mouse ephrin-A5 were established according to standard protocols. In brief, about 2 × 106 HEK293 cells were transfected with 25 µg of the respective pClNeo-based expression plasmids and were selected for about 2 weeks in standard medium (Dulbecco's modified Eagle's medium with 10% fetal calf serum and antibiotics) containing 400 µg/ml G418 (PAA Laboratories). Then individual clones were isolated, expanded, and analyzed for ephrin-A expression using ephA3-AP staining and later, Western blots. Those cell clones most strongly expressing ephrin-As were further expanded and used in this study.

Monoclonal Antibodies and Reagents-- ephA3-AP and AP were produced as described previously (23, 24); protein G-agarose is from Roche Molecular Biochemicals. Antibodies against chicken ephrin-A2 were described by Hornberger et al. (4), monoclonal antibodies to phosphotyrosine (clone 4G10), the beta 1-integrin-neutralizing antibody (clone DE9), and anti-human fyn (rabbit whole serum, used for immunoprecipitation) were from Upstate Biotechnologies. Monoclonal antibodies to fyn and caveolin-2 were from Transduction Laboratories, and the horseradish peroxidase-conjugated secondary antibodies were from Dianova.

Activation of ephrin-As by ephA3-- About 75% confluent HEK293 cell clones expressing the indicated ephrin-As were starved for 36 h in serum-free RPMI medium, detached from the dishes with prewarmed PUCKS-EDTA (5 mM KCl, 130 mM NaCl, 3 mM NaHCO3, 5 mM D-glucose, 10 mM HEPES, pH 7.0, 0.1 mM EDTA), pelleted at 1000 rpm for 5 min, washed once with serum-free RPMI medium, pelleted again, and resuspended in serum-free RPMI medium containing either 10 nM ephA3-AP or 10 nM AP. Then the cells were incubated at 37 °C for the indicated times, placed immediately on ice, and washed once with ice-cold PBS containing 1 mM Na3VO4. Subsequently the cells were solubilized at 4 °C for 10 min in Triton X-100 lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 5 mM iodoacetamide, 10 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 0.5% Triton X-100, 20 µM aprotinin, 50 microunits of leupeptin, 2 µM pepstatin, 1 mM Na3VO4). This lysate was used for Optiprep density gradient ultracentrifugation.

Purification of Detergent-insoluble Glycolipid-enriched Domains by Optiprep Density Gradient Ultracentrifugation-- The cell lysate was adjusted to 35% (v/v) in Optiprep (Nycomed, Oslo, Norway). 0.96 ml of this solution was overlaid with 3 ml of 30% Optiprep in lysis buffer, 0.5 ml of 10% Optiprep in lysis buffer, 0.4 ml of lysis buffer and was centrifuged at 42 krpm for 16 h at 4 °C in an SW 50.1 rotor. Subsequently, 0.6-ml fractions were taken from the top. The second fraction containing the white blur band between 30 and 10% Optiprep was collected as caveolin fraction, and the last fraction was collected as the soluble fraction (see also Ref. 21). The various fractions were extracted with 1% Nonidet P-40 for 5 to 10 min at room temperature and then precipitated with 10% trichloroacetic acid on ice for 15 min and spun down at 14 krpm for 15 min at 4 °C. The pellet was washed with 80% acetone at room temperature for 10 min and spun down again at 14 krpm for 15 min at 4 °C. The supernatant was discarded, and pellets were air-dried for further experiments such as Western blot analysis.

Immunoprecipitation and Immunoblotting-- The "caveolin" fraction was diluted 1:3 with 0.5% Triton X-100 lysis buffer containing protease inhibitors and was then precleared with appropriate amounts of protein G-agarose for 2 h at 4 °C under rotating conditions. Immunoprecipitations were done by incubating the precleared lysate with antibody-conjugated protein G-agarose for at least 4 h at 4 °C under rotating conditions. Subsequently the immunoprecipitate was centrifuged and washed three times with lysis buffer. SDS polyacrylamide gel electrophoresis and immunoblotting were done according to standard protocols.

Adhesion Assay-- 96-Well microtiter plates were coated with serially diluted (from 20 to 0.625 µg/ml in PBS) laminin or poly-L-lysine overnight at 4 °C and washed once with PBS. Nonspecific binding sites were blocked at room temperature for 1 h using 1% bovine serum albumin/PBS. The starved cells (36 h) were detached from the dishes with prewarmed PUCKS-EDTA, washed once, and resuspended in serum-free RPMI medium. ephA3-AP or AP was added to a final concentration of 10 nM. Subsequently, about 2 × 105 cells in 100 µl were plated per well (in triplicates) and incubated at 37 °C for 30 min. Then the medium was discarded, and remaining cells were washed once with PBS. Subsequently the cells were fixed with 0.5% paraformaldehyde/0.5% glutaraldehyde at room temperature for 30 min and stained with 0.5% crystal violet in 20% methanol at room temperature for 10 min. The cells were washed three times with H2O and were extracted with 50% ethanol/50 mM sodium citrate, pH 4.5 (50 µl/well). Absorbance was measured at 550 nm. Data shown in Figs. 1 and 6 were calculated on the basis of two to three independently performed experiments.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Increased Adhesion of ephrin-A2-expressing Cells after Activation by Its Receptor-- To characterize a possible receptor or signaling function of the GPI-anchored ephrin-A ligands, we established a HEK293 cell line stably expressing ephrin-A2. As the ephA system has been shown to be involved for example in the regulation of cell migration (25), we investigated whether treatment of these cells with their receptor changes the adhesive properties of these cells to laminin. For an activation we used ephA3-AP or AP (the latter serving as a negative control). ephA3-AP is a fusion protein of the extracellular part of the ephA3 receptor (known to bind strongly to ephrin-A2 (23)) and alkaline phosphatase. As alkaline phosphatase itself oligomerises, ephA3-AP, too, is in an oligomeric form (24) and thus might represent the "active" form of the receptor.

As shown in Fig. 1A, incubating HEK293-ephrin-A2 cells with ephA3-AP, but not AP, led to a significant increase in adhesion to laminin but not to poly-L-lysine, which indicates an activation of the integrin system. To confirm that the increase in adhesion is indeed dependent on the presence of ephrin-A ligands, we performed this assay also using the parental cell line HEK293. Here we did not observe any increase in cell adhesion after ephA3-AP treatment (data not shown). To investigate the role of integrins directly, we performed the adhesion assay in the presence of a function-blocking monoclonal antibody to beta 1-integrin, used at a concentration of 10 µg/ml (see "Experimental Procedures"). Here we observed a strong reduction in the ephA3-induced increase in adhesion, whereas a control antibody used at the same concentration did not affect this increase (Fig. 1B). Thus, activation of ephrin-As by their receptors leads to an activation of the integrin system.



View larger version (75K):
[in this window]
[in a new window]
 
Fig. 1.   Increased adhesion to laminin after stimulating HEK293-ephrin-A2 cells with ephA3. ephrin-A2-expressing cells were starved for 36 h, detached from the culture dishes, and plated in the presence of 10 nM ephA3-AP or 10 nM AP on dishes coated with increasing concentrations of laminin (0.625-20 µg/ml) or poly-L-lysine (0.625-20 µg/ml). 30 min later unbound cells were washed away. The number of adherent cells was determined using a colorimetric assay (see "Experimental Procedures"). y axis, number of adherent cells in arbitrary units. A, activation of ephrin-A2 with ephA3-AP results in a specific increase in adhesion to laminin, but not to poly-L-lysine (PLL), when compared with cells incubated with AP. B, the increase in ephA3-AP-mediated adhesiveness can be blocked by incubation with a neutralizing antibody to beta 1-integrin. Here ephrin-A2-expressing cells were incubated in the presence of ephA3-AP either with an anti-beta 1-integrin antibody (10 µg/ml) or with a control antibody (anti-human Fc; 10 µg/ml).

ephrin-A2 Is Associated with raft Microdomains-- To understand the signaling function of ephrin-A ligands more closely, we were interested in identifying those proteins that link stimulated ephrin-A ligands to the integrin system. As ephrin-A molecules are GPI-anchored, they possess no direct link to the cytosol and thus might require a "coreceptor" for exerting such a signaling function. GPI-anchored molecules are found in so called rafts, which are believed to represent platforms in which molecules involved in signal transduction are concentrated, thus a coreceptor might colocalize here with ephrin-As.

In initial experiments we investigated whether ephrin-A2 is indeed associated with rafts. A criterion for the association of a particular protein with rafts is the presence of that protein in detergent-insoluble glycolipid-enriched domains, which can be isolated because of their high lipid content by sucrose gradient centrifugation (26). Thus ephrin-A2-expressing cells were subjected to an Optiprep (sucrose) step gradient centrifugation, and individual fractions were subjected to Western blot analysis using monoclonal antibodies to ephrin-A2 and caveolin-2. Caveolins (27) are proteins that are often found associated with these rafts and might function in stabilizing the raft domains (13). These analyses showed that ephrin-A2 is contained in the same fractions as caveolin-2, indicating that ephrin-A2 is indeed localized to rafts. Fractions containing soluble proteins neither contained ephrin-A2 nor caveolin-2 (Fig. 2, A and C). This purification step considerably increased the sensitivity of our analyses, as the majority of cell proteins was contained in the nonraft fractions (data not shown).



View larger version (61K):
[in this window]
[in a new window]
 
Fig. 2.   Analysis of the tyrosine phosphorylation pattern of raft fractions after activating ephrin-A2 by ephA3. A fibroblast cell line stably expressing ephrin-A2 (HEK293-ephrin-A2) was serum-starved for 36 h, followed by an incubation with 10 nM ephA3-AP or 10 nM AP for the indicated times (0, 30, and 60 min). Subsequently raft fractions (C), as well as fractions containing soluble proteins (S), were isolated by Optiprep centrifugation and subjected to Western blot analysis using the anti-phosphotyrosine-specific antibody 4G10 (A). Then the filter was stripped and reprobed with antibodies specific for (B) fyn and (C) caveolin-2 (cav-2). alpha -Cav-2 antibodies were used to show a separation of raft-associated proteins versus soluble proteins and also to verify that similar amounts of the raft fractions had been loaded. Molecular mass markers (in kDa) are indicated to the left. Labelings to the right highlight the tyrosine phosphorylation patterns of p120, p80, and src family kinases at roughly 60 kDa. Whereas the tyrosine phosphorylation of p120 is transiently up-regulated, the phosphorylation of p80 is strongly reduced after ephrin-A activation. Apparently neither the concentration nor the phosphorylation level of fyn is changed (A and B). D, to confirm the identity of fyn, the raft fraction was immunoprecipitated (IP) using an anti-fyn antibody and was then probed with the anti-phosphotyrosine antibody 4G10 (left) and, after stripping, with a different fyn antibody (right). The left lanes in each figure show the raft fraction before immunoprecipitation.

Activation of ephrin-A2 Leads to Changes in the Tyrosine Phosphorylation Pattern of raft Proteins-- To identify proteins that might be components of an ephrin-A2 signaling pathway, we compared the raft fractions from HEK293-ephrin-A2 cells after incubation with either ephA3-AP or with AP. Using Western blot analysis we focused in particular on changes in tyrosine phosphorylation levels using phosphotyrosine-specific monoclonal antibodies. Before activation, cells were serum-starved for 36 h to reduce the considerable level of tyrosine phosphorylation of membrane proteins, which is evident for cells grown under standard conditions with serum.

As shown in Fig. 2, we indeed found such changes in the tyrosine phosphorylation pattern of proteins contained in the raft fractions after activating ephrin-A2-expressing cells with ephA3-AP but not with AP. In particular, a protein of roughly 120 kDa, which is only slightly tyrosine phosphorylated in the uninduced state, becomes strongly phosphorylated after 30 min, and later, after about 60 min, returns to a close to initial phosphorylation level. This protein was not detected in the fractions containing soluble proteins but in the same fraction as caveolin-2, suggesting that it represents a molecule specifically associated with raft fractions (Fig. 2). Additionally, proteins with a molecular mass of 70-80 kDa, which were highly tyrosine-phosphorylated before induction, became dephosphorylated after ephA3-AP treatment, with an almost complete dephosphorylation after 60 min (for simplicity, this set of proteins will be referred to in the following paragraphs as p80). These proteins also were specifically contained in the raft fraction. Thus, there are (at least) two proteins whose tyrosine phosphorylation levels were changed, in opposite directions, after activation of ephrin-A2. However, we can not exclude the possibility that the increase in p120 tyrosine phosphorylation is because of a recruitment of p120 to the raft domains after ephrin-A2 stimulation. Similarly, the down-regulation of p80 phosphorylation might be because of a lower concentration of p80 in rafts after ephrin-A2 activation.

In addition, we observed a doublet of two strongly tyrosine-phosphorylated proteins, whose phosphorylation pattern did not change after ephA3-AP treatment (Fig. 2). Reprobing filters with an anti-fyn antibody (Fig. 2) resulted in the appearance of a band at exactly the same position as after probing the filter with the phosphotyrosine-specific antibody, suggesting that one of these bands corresponds to the nonreceptor tyrosine kinase fyn (Fig. 2B). This was confirmed in an additional set of experiments. Here the raft fraction of ephA3-AP-stimulated cells was immunoprecipitated using an anti-fyn polyclonal serum and subsequently analyzed in a Western blot using firstly an anti-phosphotyrosine antibody and secondly, after stripping of the filter, an anti-fyn monoclonal antibody (Fig. 2D). Also, our analyses indicated that neither the amount nor the phosphorylation level of fyn was changed after activation of ephrin-A2 (Fig. 2, A and C). A rehybridization of the filters with an antibody against caveolin-2, as shown in Fig. 2B, demonstrated that similar amounts of raft proteins have been loaded.

Subsequently, we investigated in more detail the temporal changes that took place in the level of tyrosine phosphorylations of p120 and p80 after treating cells with ephA3-AP. As shown in Fig. 3, p120 becomes significantly tyrosine-phosphorylated only after about 15 min, thus with an apparent lag phase of about 10 min. The tyrosine phosphorylation remains at a high level for about 30 min and then decreases, leading to a faint signal 60 min after the start of ephrin-A2 activation. The dephosphorylation of p80 started earlier, that is already 5 min after ephA3-AP treatment, a significant drop in the level of tyrosine phosphorylation is apparent and with time, leads to an almost complete dephosphorylation. The expression level and tyrosine phosphorylation level of fyn was not affected within the time window investigated (Fig. 3C). We also verified that, even after a 60-min incubation with ephA3-AP, the concentration of ephrin-A2 associated with the raft fraction is not changed (Fig. 3D).



View larger version (45K):
[in this window]
[in a new window]
 
Fig. 3.   Temporal changes in the tyrosine phosphorylation of proteins localized in raft fractions after activation of ephrin-A2 by ephA3. Serum-starved HEK293-ephrin-A2 cells were incubated for the indicated times with ephA3-AP. Subsequently raft fractions were isolated and subjected to Western blot analysis. A, tyrosine phosphorylation patterns using the anti-phosphotyrosine-specific monoclonal antibody 4G10, (B) fyn, (C) cav-2, and (D) ephrin-A2. 15 min after start of activation with ephA3, there is a marked increase in the tyrosine phosphorylation of p120, which, however, is again reduced after 60 min. The tyrosine phosphorylation of p80 is significantly decreased already after 5 min. The decrease in the tyrosine phosphorylation of a protein of roughly 45 kDa is observed also after incubation with AP alone (see Fig. 2). E, cell adhesion of HEK293-ephrin-A2 cells measured at different times of activation by ephA3-AP (right bars) or AP (left bars).

When analyzing the temporal changes in cell adhesion after ephrin-A2 activation (Fig. 3E), we found that the increase in adhesion was observed only after a lag phase of at least 20 min, that is the increase in adhesion is seen clearly only after the increase in p120 tyrosine phosphorylation has occurred.

In an attempt to determine the identity of p120, we have probed the cells using ephrin-A5-AP or ephrin-A2-AP, and we have analyzed the raft fraction with selected antibodies. However, results from these experiments ruled out the possibility that p120 corresponds to an ephA receptor or focal adhesion kinase (data not shown).

Specificity of the Activated Signaling Pathway-- Next we asked whether the changes in phosphorylation observed were specific for ephrin/Eph interactions or whether other proteins such as growth factors also induce these or similar changes in tyrosine phosphorylation. For this purpose, we analyzed a number of different signaling molecules known to affect the tyrosine phosphorylation patterns of cellular proteins, such as epidermal growth factor (EGF), insulin growth factor (IGF), and bFGF. We also included fetal calf serum (FCS) in our analysis, which contains a large variety of different growth factors. We observed a decrease in the phosphorylation of p80 after FCS treatment; however, none of these factors led to changes in the tyrosine phosphorylation pattern of p120 comparable with those caused by ephA3-AP (Fig. 4).



View larger version (51K):
[in this window]
[in a new window]
 
Fig. 4.   The tyrosine phosphorylation of p120 is specifically induced by an ephrin-A2/ephA receptor interaction. After serum starvation, ephrin-A2 expressing cells were incubated for 30 min with bFGF (20 ng/ml), EGF (20 ng/ml), IGF (50 ng/ml), 10% FCS, or 10 nM ephA3-AP (the bFGF, EGF, and IGF concentrations used are at the upper limit of working concentrations according to the instructions of the suppliers). Subsequently, raft fractions from these cells were isolated and analyzed by Western blot using an anti-phosphotyrosine-specific antibody. Only ephA3-AP induced the tyrosine phosphorylation of p120, whereas both ephA3-AP and FCS treatment result in a down-regulation of p80 tyrosine phosphorylation. In a control the tyrosine phosphorylation pattern before incubation with ephA3-AP treatment is shown.

Activation of ephrin-A5 Leads to an Activation of the Same Signaling Pathway-- We then wanted to know whether the observed changes in tyrosine phosphorylation can be observed also for other ephrin-A ligands. We established HEK293 cells stably expressing either the long or the short splice form of ephrin-A5 (28) and performed the same experiments as described above for ephrin-A2. Indeed, after activation by ephA3-AP, both ligands induced the down-regulation of p80 phosphorylation and the transient up-regulation of p120 phosphorylation (Fig. 5).



View larger version (64K):
[in this window]
[in a new window]
 
Fig. 5.   The long and short splice forms of ephrin-A5 induce the same changes in tyrosine phosphorylation of raft proteins as ephrin-A2. HEK293 cell lines stably expressing either the long or the short splice form of ephrin-A5 were serum-starved for 36 h and were subsequently treated with 10 nM ephA3-AP for the indicated times. raft fractions were isolated and subjected to Western blot analysis using the phosphotyrosine-specific antibody 4G10. Similar to the results obtained with the HEK293-ephrin-A2 cell line (see Figs. 2 and 3), there is a transient increase in the amount of tyrosine-phosphorylated p120 and a rapid decrease in the tyrosine phosphorylation of p80. There is no apparent difference between the two different ephrin-A5 splice forms with respect to tyrosine phosphorylation of raft proteins.

Blocking Tyrosine Phosphorylation of p120 Abolishes the Increase in Cell Adhesion-- Our next step was to investigate more closely the inter-relationship between ephrin-As and integrins. A number of molecules are known to be involved in the regulation of integrin signaling, and we were interested in whether signaling pathways used in ephrin-A and integrin signaling share common members. We concentrated on src family kinases, which are known to be involved in integrin signaling and are required for an optimal adhesion efficiency but appear not to be essential for these events (29-33). We used the pyrazolopyrimidine PP2, which selectively inhibits src family kinases (34). This inhibitor and a closely related molecule, PP1, have both been used in a number of investigations to show an involvement of src family kinases in different developmental processes (21, 35, 36).

Treating the ephrin-A2-expressing cells with 10 µM PP2 alone, thus without stimulation by ephA3-AP, led to only a small reduction in the adhesiveness of these cells (Fig. 6). However, the strong increase in adhesion typically seen after ephA3-stimulation (see Figs. 1 and 6) was prevented by PP2, i.e. by blocking src family kinases. The incubation in the presence of 10 µM PP3, which is a structurally closely related but functionally inactive compound to PP2, had no effect on the increase in cell adhesion (Fig. 6).



View larger version (90K):
[in this window]
[in a new window]
 
Fig. 6.   Blocking src family kinases greatly reduces the increase in cell adhesion seen after stimulating ephrin-A2-expressing cells with ephA3-AP. Serum-starved ephrin-A2 expressing cells were treated for 4 h with PP2 or PP3. Then the cells were detached from the culture dishes and plated in the presence of ephA3-AP or AP on dishes coated with increasing concentrations of laminin (0.625-20 µg/ml). 30 min later unbound cells were washed away. The number of adherent cells was determined using a colorimetric assay (see "Experimental Procedures"). y axis, number of adherent cells in arbitrary units. The increase in ephA3-AP mediated adhesiveness of HEK293-ephrin-A2 cells can be inhibited by treating cells with 10 µM PP2 (a selective src family kinase inhibitor) but not with PP3, a very similar but functionally inactive compound to PP2. For details see Fig. 1 and "Experimental Procedures."

In parallel to these binding assays, we performed Western blot analyses of raft fractions from ephA3-AP-treated cells, which showed that PP2 pretreatment of these cells almost completely abolished the increase in tyrosine phosphorylation of p120, whereas PP3 did not affect this pattern (Fig. 7).



View larger version (85K):
[in this window]
[in a new window]
 
Fig. 7.   The tyrosine phosphorylation of p120 is abolished after blocking src family kinases. A, Serum-starved HEK293-ephrin-A2 cells were treated for 4 h with 10 µM PP2, a selective src family kinase inhibitor. Subsequently cells were incubated with 10 nM ephA3-AP for the indicated periods of time. For control, a second batch of cells was treated identically but with added PP3, a very similar but functionally inactive compound to PP2. Then cells were lysed, and raft fractions were isolated and subjected to Western blot analysis. It is shown here that in the presence of PP2, but not PP3, the increase in tyrosine phosphorylation of p120 is almost completely abolished. B, to indicate that similar amounts of raft proteins have been loaded, the stripped filter was reprobed with an anti-caveolin-2 antibody.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this report we have shown that binding of ephA3 to ephrin-A-expressing cells leads to an activation of the integrin system and an increased tyrosine phosphorylation of a 120-kDa raft protein. Both the increase in adhesion and in tyrosine phosphorylation of p120 can be abolished by inhibiting the function of src family kinases. Besides p120, we identified a set of proteins having a molecular mass of about 80 kDa, whose tyrosine phosphorylation was down-regulated after ephrin-A stimulation.

Signaling Complexes in raft Microdomains-- It has been proposed that raft microdomains serve as platforms in the membrane, within which molecules involved in signaling to the cytosol are organized (7, 12, 13). Both GPI-anchored ephrin-A ligands and B-class ephrins, which are transmembrane-anchored, are found in these structures. Whereas A-ligands appear to be constitutively associated with these rafts, the incorporation of B-ligands in these structures might be regulated, as ephrin-Bs without their cytoplasmic tail no longer associate with rafts (37), suggesting an active (regulated) transport of B-ephrins into and out of rafts. Interaction of ephB receptors with their ligands results in the phosphorylation of highly conserved tyrosines in the intracellular domain of the ligands, which then might serve as binding sites for other signaling molecules (37-41).

After stimulation of ephrin-A2-expressing cells with ephA3-AP, we observed an increase in cell adhesion, which could be abolished by using a neutralizing monoclonal antibody to beta 1-integrin, indicating the existence of an ephrin-A-dependent signaling pathway controlling integrin function. The mechanism by which ephrin-As exert this function, e.g. signal into the cytosol, is poorly understood. It is quite possible that a communication between ephrin-As (bound to the outer leaflet of the membrane) and intracellular signaling molecules such as lipidated src family kinases (bound to the inner leaflet of the membranes) is mediated by (conformational changes of) transmembrane proteins. The proteins we have identified on the basis of their presence in raft membranes and their differential tyrosine phosphorylation pattern in response to ephrin/Eph interactions represent candidates for such a role. p120 is only slightly phosphorylated in the unstimulated state but becomes strongly tyrosine-phosphorylated after ephrin-A activation. We cannot exclude the possibility that the increase in tyrosine phosphorylation of p120 is because of a recruitment of already tyrosine-phosphorylated p120 to the raft domains. However, we think this is unlikely, because the increase in p120 tyrosine phosphorylation can be blocked by inhibiting src family kinases. It remains to be investigated whether a similar modification of p120 can be observed also after clustering of other GPI-anchored proteins expressed at similar levels in HEK293 cells.

It is noteworthy that the strong increase in p120 tyrosine phosphorylation occurs only after a lag phase of about 10 min, suggesting the involvement of other signaling components. Possibly the lag phase is correlated with changes in the structure or composition of ephrin-A-containing raft microdomains. Thus treatment with oligomeric ephA3-AP might lead to a clustering of ephrin-A2 and a concomitant fusion of initially smaller raft microdomains, which results, by an unknown mechanism, in an activation of src family kinases, p120 tyrosine phosphorylation, and integrin activation. In good agreement with p120 playing a role in coupling ephrin-A activation to integrin activation, we have shown here (using a specific src family kinase inhibitor) that blocking p120 tyrosine phosphorylation correlates with an abolishment of the increase in cell adhesion. In further support, the increase in cell adhesion occurs subsequent to the increase in p120 tyrosine phosphorylation, which thus supports the concept that p120 phosphorylation is involved in the control of cell adhesion rather than its being a consequence. The p80 protein might not be involved in this process, as its dephosphorylation was observed for example also after FCS treatment, which on the other hand does not affect cell adhesion.

Interestingly, activation of ephA receptors leads to a suppression of integrin function and to an inhibition of cell spreading and migration (of fibroblast cells) (42-45). Therefore, the unexpected picture arises that activation of ephAs and ephrin-As might contribute to the regulation of a similar intracellular signaling pathway but in opposite directions. It appears that interaction between ephA-expressing and ephrin-A-expressing cells results in a decrease in adhesion of the ephA-expressing cells and an increase in adhesion of the ephrin-A-expressing cells. It will be of interest to investigate the behavior of cells expressing both ephrin-As and ephAs simultaneously and to study the responses of an activation of ephAs or ephrin-As or both. The physiological meaning of these regulations in vivo is not known, but understanding this process might contribute to an understanding of the development of the retinotectal projection, where on subpopulations of retinal axons ephrin-As and ephAs are coexpressed.

Specificity of the Tyrosine Phosphorylation of p120 and p80-- Recently, in an approach similar to the one used here, Davy et al. (21) identified a number of proteins whose tyrosine phosphorylation level increased after binding of ephA5-Fc to an ephrin-A5-expressing cell line. They found most prominently a 75-80-kDa protein, which became highly phosphorylated after ephrin-A2 treatment. However, stimulation with bFGF induced the tyrosine phosphorylation of the same protein, which indicates the activation of a more general, but not ephrin-A-specific, signaling pathway. The tyrosine phosphorylation level of the p70-80 protein we identified was quickly down-regulated after ephrin-A activation and was also not specific for an ephrin-A signaling pathway. Thus, it is unclear whether these two sets of proteins are the same, albeit of a rather similar, molecular weight. Overall, although the approaches of Davy et al. (21) and our own group appear to be similar, there are some differences in the experimental set-up, like the use of serum-starved cells, and these might explain the different results observed. A molecular identification of, for example, the 80-kDa protein/s will help answer this puzzle.

In contrast, the up-regulation of tyrosine phosphorylation of p120 was specific for the ephrin/ephA receptor interaction within the limits of molecules tested here. Thus, it was not seen after treatment of cells with growth factors such as bFGF, IGF, or EGF or with fetal calf serum, which contains a large variety of different growth factors. A characterization of a 120-kDa protein was not reported by Davy et al. (21). The precise role of p120 in the process linking ephrin-A activation to integrin activation is presently unclear, thus further experiments will be directed toward a more detailed characterization of this molecule.


    ACKNOWLEDGEMENTS

We thank F. Bonhoeffer for support and discussion. We also thank Bernd Knöll, Matthias Knirr, and Rosemary Drescher for comments on the manuscript.


    FOOTNOTES

* This work was supported in part by grants from the Deutsche Forschungsgemeinschaft (to U. D.)The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: MRC Centre for Developmental Neurobiology, King's College London, 4th Floor, New Hunt's House, Guy's Campus, London SE1 1UL, United Kingdom. Tel.: 0044-20-7848-6411; Fax: 0044-20-7848-6798; E-mail: uwe.drescher@kcl.ac.uk.

Published, JBC Papers in Press, October 25, 2000, DOI 10.1074/jbc.M008127200


    ABBREVIATIONS

The abbreviations used are: GPI, glycosylphosphatidylinositol; PBS, phosphate-buffered saline; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; IGF, insulin growth factor; FCS, fetal calf serum; AP, alkaline phosphatase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Drescher, U., Bonhoeffer, F., and Müller, B. K. (1997) Curr. Opin. Neurobiol. 7, 75-80[CrossRef][Medline] [Order article via Infotrieve]
2. Flanagan, J. G., and Vanderhaeghen, P. (1998) Annu. Rev. Neurosci. 21, 309-345[CrossRef][Medline] [Order article via Infotrieve]
3. O'Leary, D. D. M., Yates, P. A., and McLaughlin, T. (1999) Cell 98, 255-269
4. Hornberger, M. R., Dütting, D., Ciossek, T., Yamada, T., Handwerker, C., Lang, S., Weth, F., Huf, J., Wessel, R., Logan, C., Tanaka, H., and Drescher, U. (1999) Neuron 22, 731-742[Medline] [Order article via Infotrieve]
5. Dütting, D., Handwerker, C., and Drescher, U. (1999) Dev. Biol. 216, 297-311[CrossRef][Medline] [Order article via Infotrieve]
6. Feldheim, J., Kim, Y.-I., Bergemann, A. D., Frisén, J., Barbacid, M., and Flanagan, J. G. (2000) Neuron 25, 563-574[Medline] [Order article via Infotrieve]
7. Simons, K., and Ikonen, E. (1997) Nature 387, 569-572[CrossRef][Medline] [Order article via Infotrieve]
8. Anderson, R. G. W. (1998) Annu. Rev. Biochem. 67, 199-225[CrossRef][Medline] [Order article via Infotrieve]
9. Brown, D. A., and London, E. (1998) Annu. Rev. Cell Dev. Biol. 14, 111-136[CrossRef][Medline] [Order article via Infotrieve]
10. Varma, R., and Mayor, S. (1998) Nature 394, 798-801[CrossRef][Medline] [Order article via Infotrieve]
11. Friedrichson, T., and Kurzchalia, T. V. (1998) Nature 394, 802-805[CrossRef][Medline] [Order article via Infotrieve]
12. Brown, D. A., and London, E. (2000) J. Biol. Chem. 275, 17221-17224[Free Full Text]
13. Harder, T., and Simons, K. (1997) Curr. Opin. Cell Biol. 9, 534-542[CrossRef][Medline] [Order article via Infotrieve]
14. Jacobson, K., and Dietrich, C. (1999) Trends Cell Biol. 9, 87-91[CrossRef][Medline] [Order article via Infotrieve]
15. Peles, E., Nativ, M., Lustig, M., Grumet, M., Schilling, J., Martinez, R., Plowman, G. D., and Schlessinger, J. (1997) EMBO J. 16, 978-988[Abstract/Free Full Text]
16. Doherty, P., Singh, A., Rimon, G., Bolsover, S. R., and Walsh, F. S. (1993) J. Biol. Chem. 122, 181-189
17. Economides, A. N., Ravetch, J. V., Yancopoulos, G. D., and Stahl, N. (1995) Science 270, 1351-1353[Abstract]
18. Massague, J. (1996) Nature 382, 29-30[CrossRef][Medline] [Order article via Infotrieve]
19. Buj-Bello, A., Adu, J., Pinon, L. G., Horton, A., Thompson, J., Rosenthal, A., Chinchetru, M., Buchman, V. L., and Davies, A. M. (1997) Nature 387, 721-724[CrossRef][Medline] [Order article via Infotrieve]
20. Rodgers, W., and Rose, J. K. (1996) J. Cell Biol. 135, 1515-1523[Abstract]
21. Davy, A., Gale, N. W., Murray, E. W., Klinghofer, R. A., Soriano, P., Feuerstein, C., and Robbins, S. M. (1999) Genes Dev. 13, 3125-3135[Abstract/Free Full Text]
22. Davy, A., Feuerstein, C., and Robbins, S. M. (2000) J. Neurochem. 74, 676-683[CrossRef][Medline] [Order article via Infotrieve]
23. Monschau, B., Kremoser, C., Ohta, K., Tanaka, H., Kaneko, T., Yamada, T., Handwerker, C., Hornberger, M. R., Löschinger, J., Pasquale, E. B., Siever, D. A., Verderame, M. F., Müller, B. K., Bonhoeffer, F., and Drescher, U. (1997) EMBO J. 16, 1258-1267[Abstract/Free Full Text]
24. Ciossek, T., Monschau, B., Kremoser, C., Löschinger, J., Lang, S., Müller, B. K., Bonhoeffer, F., and Drescher, U. (1998) Eur. J. Neurosci. 10, 1574-1580[CrossRef][Medline] [Order article via Infotrieve]
25. Wilkinson, D. G. (2000) Int. Rev. Cytol. 196, 177-244[Medline] [Order article via Infotrieve]
26. Schroeder, R., London, E., and Brown, D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12130-12134[Abstract/Free Full Text]
27. Parton, R. G. (1996) Curr. Opin. Cell Biol. 8, 542-548[CrossRef][Medline] [Order article via Infotrieve]
28. Flenniken, A. M., Gale, N. W., Yancopoulos, G. D., and Wilkinson, D. G. (1996) Dev. Biol. 179, 382-401[CrossRef][Medline] [Order article via Infotrieve]
29. Lauffenburger, D. A., and Horwitz, A. F. (1996) Cell 84, 359-369[Medline] [Order article via Infotrieve]
30. Parsons, J. T., and Parsons, S. J. (1997) Curr. Opin. Cell Biol. 9, 187-192[CrossRef][Medline] [Order article via Infotrieve]
31. Thomas, S. M., and Brugge, J. S. (1997) Annu. Rev. Cell Dev. Biol. 13, 513-609[CrossRef][Medline] [Order article via Infotrieve]
32. Cary, L. A., Han, D. C., and Guan, J. L. (1999) Histol. Histopathol. 14, 1001-1009[Medline] [Order article via Infotrieve]
33. Giancotti, F. G., and Ruoslathi, E. (1999) Science 285, 1028-1032[Abstract/Free Full Text]
34. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connelly, P. A. (1996) J. Biol. Chem. 271, 695-701[Abstract/Free Full Text]
35. Osterhout, D. J., Wolven, A., Wolf, R. M., Resh, M. D., and Chao, M. V. (1999) J. Cell Biol. 145, 1209-1218[Abstract/Free Full Text]
36. Yamauchi, J., Kaziro, Y., and Itoh, H. (1999) J. Biol. Chem. 274, 1957-1965[Abstract/Free Full Text]
37. Brückner, K., Labrador, J. P., Scheiffele, P., Herb, A., Seeburg, P. H., and Klein, R. (1999) Neuron 22, 511-524[Medline] [Order article via Infotrieve]
38. Brückner, K., Pasquale, E. B., and Klein, R. (1997) Science 275, 1640-1643[Abstract/Free Full Text]
39. Holland, S. J., Gale, N. W., Mbamalu, G., Yancopoulos, G. D., Henkemeyer, M., and Pawson, T. (1996) Nature 383, 722-725[CrossRef][Medline] [Order article via Infotrieve]
40. Xu, Q., Mellitzer, G., Robinson, V., and Wilkinson, D. G. (1999) Nature 399, 267-271[CrossRef][Medline] [Order article via Infotrieve]
41. Mellitzer, G., Xu, Q., and Wilkinson, D. G. (1999) Nature 400, 77-81[CrossRef][Medline] [Order article via Infotrieve]
42. Miao, H., Burnett, E., Kinch, M., Simon, E., and Wang, B. (2000) Nat. Cell Biol. 2, 62-69[CrossRef][Medline] [Order article via Infotrieve]
43. Becker, E., Huynh-Do, U., Holland, S., Pawson, T., Daniel, T. O., and Skolnik, E. Y. (2000) Mol. Cell. Biol. 20, 1537-1545[Abstract/Free Full Text]
44. Huynh-Do, U., Stein, E., Lane, A. A., Liu, H., Ceretti, D. P., and Daniel, T. O. (1999) EMBO J. 18, 2165-2173[Abstract/Free Full Text]
45. Zou, J. X., Wang, B., Kalo, M. S., Zisch, A. H., Pasquale, E. B., and Ruoslahti, E. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13813-13818[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.